Arginine‐stimulated copeptin in children and adolescents
Authors' conclusion
Stimulated copeptin is a promising parameter for the differential diagnosis of polyuria-polydipsia syndrome. However, the low copeptin increase after arginine and the high limit of quantification of the assay are problematic for use in paediatrics.
Study context
- Population
- Children and adolescents who underwent arginine or GHRH-arginine stimulation to test GH secretory capacity, 2018–2022
- Participants
- 72 children
- Exposure
- AVP deficiency (AVPD) vs non-AVPD
- AVPD (CDI)n = 4
- non-AVPD (non-CDI)n = 68reference
- Outcome
- Copeptin (BRAHMS Copeptin proAVP Kryptor) at baseline, 30 and 60 min after arginine; pediatric reference values
- Follow-up
- Baseline, 30 and 60 min
Methodological detailsmonocentric, retrospective analysis of donated residual serum samples
- Monocentric
- Retrospective analysis of donated residual serum samples
Main finding
As reported in the abstract
Copeptin in non-AVPD patients
- Baseline copeptin range, non-AVPD
- 1.3-44.4 pmol/L
- 30-min copeptin range after arginine, non-AVPD
- 1.6-40.4 pmol/L
- Median baseline copeptin
- 5.6 pmol/L
- Median peak copeptin
- 8.0 pmol/L
- 2.5th percentile of baseline copeptin
- 2.1 pmol/L
- 2.5th percentile of peak copeptin
- 3.3 pmol/L
Observational data: associations, not effects.
Further findings
Correlation of copeptin with age
- Copeptin increase vs age, R (p = .011)
- −.405
- Peak copeptin vs age, R (p = .0072)
- −.335
- Not related to gender, BMI (SD score) or GH secretion
Copeptin in AVPD (CDI) patients
- In the 4 AVPD patients, baseline or stimulated copeptin was below the 2.5th percentile of non-AVPD patients
Original publication
Arginine‐stimulated copeptin in children and adolescents. Clin Endocrinol (Oxf). Published 5 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →